Article Text

Download PDFPDF
Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?
  1. M Porta1,
  2. B González2,
  3. S Márquez3,
  4. L Artazcoz4
  1. 1
    Institut Municipal d’Investigació Mèdica, Universitat Autònoma de Barcelona, Spain
  2. 2
    Universidad de Las Palmas de Gran Canaria, Spain
  3. 3
    Fundación Instituto de Investigación en Servicios de Salud, Sevilla, Spain
  4. 4
    Centro de Análisis y Programas Sanitarios, Barcelona, Spain
  1. Professor M Porta, IMIM & UAB, Carrer del Dr Aiguader 88, E-08003 Barcelona, Catalonia, Spain; mporta{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Marketing of human papillomavirus (HPV) vaccines is a scientific success for the biomedical research community and industry. Yet, exciting as it rightly is to scientists, technological progress does not guarantee public health impact, as anyone who cares for the public good knows. Trials of HPV vaccines, for instance, have had a limited duration with respect to the lifetime risk (and, hence, prevention) of cervical cancer; this is one reason why the long-term, true effectiveness of HPV vaccines to substantially decrease the population burden of cervical cancer and related pathologies is still unproven, even in countries with a high burden. In many societies worldwide, HPV infection is almost always benign, slow, naturally reversible and can be properly controlled with non-aggressive measures that …

View Full Text


  • Competing interests: None declared.

Linked Articles

  • In this issue
    Mauricio L Barreto